Straumann Holding AG (SAUHF) Stock Price & Analysis
Straumann Holding AG (SAUHF) — price $129.48 (0.00%), as of the Nov 20, 2026 trading session; market cap $20.8B. Expected results Feb 24, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Straumann Holding AG · SAUHF · Healthcare · Medical - Instruments & Supplies
Straumann Holding AG is a global provider of dental solutions, specializing in restoring and correcting teeth.
Price as of Nov 20, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $129.48 | |
| Change on the day | 0.00% | |
| 52-week range | $93.18–$135.00 | |
| Market capitalisation | $20.8B | — |
| Price / earnings (trailing) | 45.97 | |
| Shares traded on the day | 200 | |
| Beta (volatility vs the S&P 500) | 1.5 | |
| Dividends per share (last 12 months) | $1.62 | |
| Dividend yield (last 12 months) | 1.26% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
And we will, for differentiation, potentially have the opportunity to launch Neodent by mid-2027.
Guillaume Daniellot · Statement from
And finally, when it comes to 2027, you know that they will -- we will have a major product launch for Neodent starting obviously by midyear in Brazil and Latin America, which is the new implant system from Neodent, which is going to be the GT Plus replacing the existing already very successful implant system.
Guillaume Daniellot · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Straumann Holding AG (SAUHF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 24, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Straumann Holding AG (SAUHF), and what does it report?
Short answer
Straumann Holding AG is a global provider of dental solutions, specializing in restoring and correcting teeth. Healthcare / Medical Instruments & Supplies SEC filing business address: 120 Broadway, 32ND Floor, NEW York, NY, 10271. It employs 11,824 people and is led by Guillaume Daniellot. In Q2 FY2026 it reported revenue of CHF 1.37B and net income of CHF 249M. The market values it at $20.8B.
What do the latest results show for Straumann Holding AG (SAUHF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CHF 1.37B. Against analyst estimates the company has EPS beat 1 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.71B Aug 19, 2026
- Latest report · revenue estimate
- $1.70B Aug 19, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 19, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 19, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 19, 2026 | $1.71B | $1.70B | $2.0300 | $1.9700 |
| Apr 29, 2026 | $1.59B | $1.57B | $1.6700 | $1.7700 |
| Jun 30, 2025 | $1.70B | $1.71B | $1.8600 | $2.2600 |
| Feb 19, 2025 | $1.36B | $1.35B | $1.5100 | $1.5200 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CHF 1.37B | CHF 249M | CHF 1.56 (diluted) |
| Q4 FY2025 | CHF 1.26B | CHF 120M | CHF 0.75 (diluted) |
| Q2 FY2025 | CHF 1.35B | CHF 236M | CHF 1.49 (diluted) |
| Q4 FY2024 | CHF 1.23B | CHF 158M | CHF 0.76 (diluted) |
What are the financial strengths and risks for Straumann Holding AG (SAUHF)?
Short answer · as of
The distress and quality screens read Altman Z 8.93 · Piotroski F 5. Trailing ratios: ROE 16.7% · ROA 9.5% · current ratio 2.26 · earnings yield 2.1% · free-cash-flow yield 2.2%.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Rich valuation — a P/E of 45.97 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Straumann Holding AG (SAUHF)?
Short answer · as of
The next earnings report is expected on Feb 24, 2027.
What management is planning
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SAUHF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SAUHF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Straumann Holding AG (SAUHF) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the SAUHF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SAUHF a good stock to buy?
Stock Expert AI does not rate SAUHF buy, sell or hold. Straumann Holding AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SAUHF stock price today?
The last price recorded for Straumann Holding AG (SAUHF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Straumann Holding AG manage patent expiration risks?
Straumann Holding AG actively manages patent expiration risks by investing in research and development to innovate and introduce new products.
What are the key factors to evaluate for SAUHF?
Evaluate SAUHF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This strategy will not only drive sales but also position Straumann as a thought leader in dental education. Not financial advice.
How frequently does SAUHF data refresh on this page?
SAUHF's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SAUHF's recent stock price performance?
Straumann Holding AG (SAUHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Leading position in the dental implant market with a strong brand. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SAUHF overvalued or undervalued right now?
The trailing P/E of Straumann Holding AG (SAUHF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SAUHF before investing?
Before investing in Straumann Holding AG (SAUHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 42 figures on this page — 2 from SEC filings and earnings calls, 31 from Financial Modeling Prep (FMP), 4 with no recorded source, 4 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com